Advances in the Translational Science of Dermatitis

Sara Bilimoria; Kyle Tegtmeyer; Peter Lio

doi:10.1016/j.iac.2021.04.001

Advances in the Translational Science of Dermatitis

Immunol Allergy Clin North Am. 2021 Aug;41(3):361-373. doi: 10.1016/j.iac.2021.04.001. Epub 2021 Jun 5.

Authors

Sara Bilimoria¹, Kyle Tegtmeyer¹, Peter Lio²

Affiliations

¹ Northwestern University Feinberg School of Medicine, 363 West Erie Street, Suite 350, Chicago, IL 60616, USA.
² Northwestern University Feinberg School of Medicine, 363 West Erie Street, Suite 350, Chicago, IL 60616, USA. Electronic address: peterlio@gmail.com.

PMID: 34225894
DOI: 10.1016/j.iac.2021.04.001

Abstract

The cycle of converting mechanistic insight into therapeutic interventions is called translational science. It has been relatively sluggish in atopic dermatitis (AD), but finally pathomechanisms have been identified and therapeutic targets selected and refined. From inflammatory mediators, skin barrier enhancement, itch relief, and alteration of the microbiota, several therapies have been proposed and are actively being studied for AD, suggesting an end to the drought of innovation.

Keywords: Atopic dermatitis; Pathophysiology; Therapeutics; Translational medicine.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Dermatitis, Atopic* / therapy
Humans
Inflammation Mediators
Microbiota*
Skin

Substances

Inflammation Mediators